Therapeutic Effect of New Biologics in Crohn's Disease
Launched by SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jun 10, 2021
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effects of two new treatment options, Ustekinumab (UST) and Vedolizumab (VED), for people with Crohn's disease, which is a type of inflammatory bowel disease. The researchers want to find out how well these medications work over both short and long periods and what side effects they might cause. They are also looking to understand what factors might help predict how effective these treatments will be for different patients.
To participate in this trial, you must be an adult who has been diagnosed with Crohn's disease and is receiving one of these new biologic treatments. Unfortunately, if your medical records are incomplete or if you have not been followed up properly after beginning treatment, you would not be eligible to join. As a participant, you can expect to be monitored for your response to the medications and any side effects you may experience, contributing valuable information to help improve treatment options for others with Crohn's disease in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Consecutive adult patients with confirmed diagnosis of Crohn's disease and administration of new type biologics.
- Exclusion Criteria:
- • loss of follow-up, incomplete clinical data, without confirmed diagnosis
About Sixth Affiliated Hospital, Sun Yat Sen University
The Sixth Affiliated Hospital of Sun Yat-sen University is a leading medical institution in China, dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent academic hospital, it integrates clinical practice with research excellence, fostering collaboration among multidisciplinary teams to enhance medical knowledge and improve patient outcomes. The hospital is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, aiming to contribute to the global scientific community and support the development of new therapies and interventions. With a focus on translational medicine, the Sixth Affiliated Hospital actively engages in pioneering studies that address critical health challenges and promote evidence-based practices in diverse medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials